CA2482445A1 - Amonafide salts - Google Patents

Amonafide salts Download PDF

Info

Publication number
CA2482445A1
CA2482445A1 CA002482445A CA2482445A CA2482445A1 CA 2482445 A1 CA2482445 A1 CA 2482445A1 CA 002482445 A CA002482445 A CA 002482445A CA 2482445 A CA2482445 A CA 2482445A CA 2482445 A1 CA2482445 A1 CA 2482445A1
Authority
CA
Canada
Prior art keywords
acid
amonafide
compound
aliphatic
tricarboxylic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002482445A
Other languages
English (en)
French (fr)
Inventor
Alfred M. Ajami
David Barlow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Antisoma Research Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2482445A1 publication Critical patent/CA2482445A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/14—Aza-phenalenes, e.g. 1,8-naphthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Lubricants (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
CA002482445A 2002-04-22 2003-04-22 Amonafide salts Abandoned CA2482445A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/128,129 2002-04-22
US10/128,129 US6693198B2 (en) 2002-04-22 2002-04-22 Amonafide salts
PCT/US2003/012619 WO2003089415A1 (en) 2002-04-22 2003-04-22 Amonafide salts

Publications (1)

Publication Number Publication Date
CA2482445A1 true CA2482445A1 (en) 2003-10-30

Family

ID=29248438

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002482445A Abandoned CA2482445A1 (en) 2002-04-22 2003-04-22 Amonafide salts

Country Status (9)

Country Link
US (2) US6693198B2 (https=)
EP (1) EP1499595B1 (https=)
JP (2) JP4630518B2 (https=)
AT (1) ATE359273T1 (https=)
AU (1) AU2003221771B2 (https=)
CA (1) CA2482445A1 (https=)
DE (1) DE60313156T2 (https=)
ES (1) ES2287463T3 (https=)
WO (1) WO2003089415A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050239816A1 (en) * 2002-04-22 2005-10-27 Xanthus Life Sciences, Inc. Amonafide salts
US6693198B2 (en) 2002-04-22 2004-02-17 Xanthus Life Sciences, Inc. Amonafide salts
WO2004004716A1 (en) * 2002-07-08 2004-01-15 Chemgenex Pharmaceuticals Limited Naphthalimide synthesis including amonafide synthesis and pharmaceutical preparations thereof
AU2005209845A1 (en) * 2004-01-30 2005-08-18 Chemgenex Pharmaceuticals, Inc. Naphthalimide dosing by N-acetyl transferase genotyping
BRPI0510719A (pt) * 2004-05-05 2007-11-20 Unibioscreen Sa derivados de naftalimida, composição farmacêutica, uso e método de preparação dos mesmos
WO2005117893A2 (en) * 2004-06-04 2005-12-15 Chemgenex Pharmaceuticals, Inc. Methods of treating cellular proliferative disease using naphthalimide and parp-1 inhibitors
FR2898902B1 (fr) * 2006-03-24 2010-09-10 Oreal Colorants particuliers de type naphtalimide, composition tinctoriale comprenant au moins un tel colorant, procede de mise en oeuvre et utilisations
ES2338193B8 (es) * 2008-02-25 2011-07-19 Centro Atlantico Del Medicamento, S.A. Nuevas sales de amonafide.
NZ779754A (en) 2009-01-16 2023-04-28 Exelixis Inc Malate salt of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl] oxy} phenyl)-n’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
CN102718709A (zh) * 2011-03-30 2012-10-10 北京德众万全药物技术开发有限公司 一种制备氨萘非特的新方法
CN109490291B (zh) * 2018-11-20 2021-05-11 上海应用技术大学 基于吸电子基取代的1,8-萘酰亚胺类化合物作为氟离子的显色试剂的用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES459497A1 (es) * 1977-06-04 1978-04-16 Made Labor Sa Un metodo para la preparacion industrial de naftalimidas y sus derivados.
US4614820A (en) * 1983-04-01 1986-09-30 Warner-Lambert Co. 3,6-disubstituted-1,8-naphthalimides
US4499266A (en) * 1983-04-01 1985-02-12 Warner-Lambert Company 3,6-Dinitro-1,8-naphthalimides
US5183821A (en) 1983-09-19 1993-02-02 Laboratories Knoll, S.A. Method for treating leukemias using N-(2-dimethylaminoethyl)-3-amino-1,8-naphthalimide for treating leukemias and solid tumors
US4665071A (en) 1984-02-21 1987-05-12 Warner-Lambert Company 3,6-disubstituted-1,8-naphthalimides and methods for their production and use
DE3614414A1 (de) * 1986-04-29 1987-11-05 Knoll Ag Neue benzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
DE3635711A1 (de) * 1986-10-21 1988-04-28 Knoll Ag 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
DE3922771A1 (de) * 1989-07-11 1991-01-24 Knoll Ag Amonafide-salze
US5420137A (en) 1989-07-11 1995-05-30 Knoll Ag Amonafide salts
DE4106122A1 (de) * 1991-02-27 1992-09-03 Bayer Ag Neue naphthalimide, diese enthaltende toner und die verwendung der neuen naphthalimide als additive fuer toner
CN1330638A (zh) * 1998-11-25 2002-01-09 默克专利股份公司 取代的苯并[de]异哇啉－1,3－二酮
EP1274458B1 (en) 2000-04-12 2005-09-28 ChemGenex Pharmaceuticals, Inc. Compositions containing a naphthalmide and an antiproliferative agent
US6693198B2 (en) 2002-04-22 2004-02-17 Xanthus Life Sciences, Inc. Amonafide salts

Also Published As

Publication number Publication date
EP1499595B1 (en) 2007-04-11
JP2003321452A (ja) 2003-11-11
AU2003221771A1 (en) 2003-11-03
JP2010006831A (ja) 2010-01-14
ES2287463T3 (es) 2007-12-16
WO2003089415A1 (en) 2003-10-30
JP4630518B2 (ja) 2011-02-09
US6693198B2 (en) 2004-02-17
AU2003221771B2 (en) 2007-02-15
DE60313156T2 (de) 2007-12-13
US20030203932A1 (en) 2003-10-30
US20040132763A1 (en) 2004-07-08
DE60313156D1 (de) 2007-05-24
US6989390B2 (en) 2006-01-24
ATE359273T1 (de) 2007-05-15
EP1499595A1 (en) 2005-01-26

Similar Documents

Publication Publication Date Title
JP2010006831A (ja) アモナフィド塩
US7989494B2 (en) Polymorphs of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide
JPWO2020138481A1 (ja) ピロリジン化合物の結晶
US20080275019A1 (en) Metal complex protein kinase inhibitors
CN115260193A (zh) 用于治疗狂犬病的化合物及其方法
KR20240021239A (ko) Cdk 키나아제 억제제로 사용되는 화합물 및 이의 용도
NO324594B1 (no) Nye indolderivater, fremgangsmate for fremstilling derav og deres anvendelse og medikamenter inneholdende derivatene.
HUP0200133A2 (en) Piperidine and piperazine derivatives as inhibitors of the abetha fibril formation, process for their preparation and pharmaceutical compositions containing them
KR20240038017A (ko) 울로데신 염
JP2004518757A (ja) 金属核に基づく酸化窒素供与体
ES2223570T3 (es) Intermedios para la produccion de derivados de acido carboxilico de estructura quinolona.
ES2391371T3 (es) Derivados de la 2-trifluorometilnicotinamida como agentes para aumentar el HDL-colesterol
US20050239816A1 (en) Amonafide salts
US3651086A (en) 5-aminomethyl-4 5 6 7-tetrahydro-4-oxoindoles
JPH06228112A (ja) （１ｈ，４ｈ）キノキサリン誘導体
HRP950250A2 (en) Novel dihydrodibenzoquinolinediones
US11136332B2 (en) Morphic forms of marizomib and uses thereof
WO2002070480A1 (es) Derivados de glutarimida como agentes terapeuticos
CN115433166B (zh) 一种选择性丁酰胆碱酯酶抑制剂及其制备方法和应用
CN102617465A (zh) 他克林-咖啡酸杂联体,其制备方法及其药物组合物
TW202600556A (zh) Ｋｉｆ１８ａ抑制劑的可藥用鹽、晶型及其製備方法和用途
JP2025533592A (ja) テトラリン系誘導体の薬学的に許容される塩、結晶型及び調製方法
HK40053743A (en) Compound for treatment of rabies and method for treatment of rabies
CN115052661A (zh) 化合物和利用其的药物
Chernyshev et al. Full Text HTML

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued